Recent studies indicate that dual inhibition of DNMTs and EZH2 exhibits synergistic antineoplastic activity against human myeloid leukemia cells [30], and can resensitize the resistant myeloma cells to both lenalidomide and pomalidomide in vitro [31]. This evidence concerns the gene EZH2 and myeloid leukemia.